Search
Lisocabtagene maraleucel
go.drugbank.com/drugs/DB16582ApprovedInvestigational[L43322] In 2025, the FDA also approved lisocabtagene maraleucel as the first CAR T-cell therapy in the United States for adult patients with relapsed or refractory marginal zone lymphoma (MZL). … [A228493] Despite the adverse reactions, the majority of patients given lisocabtagene maraleucel reported an overall increase in quality of life over a 1 year period.
Pertuzumab
go.drugbank.com/drugs/DB06366ApprovedInvestigationalIt was first approved by the FDA in 2012 for use with [docetaxel] and another HER2-targeted monoclonal antibody, [trastuzumab], in the treatment of metastatic HER2-positive breast cancer. … Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence.
Products: Perjeta 420 mg concentrate for solution for infusion, PERJETA CONCENTRATE FOR SOLUTION FOR INFUSION 420MG/14MLLiotrix
go.drugbank.com/drugs/DB01583ApprovedIt consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. … Administration of levothyroxine alone is sufficient for maintaining serum T4 and T3 levels in most patients and combination hormone replacement therapy generally offers no therapeutic advantage.
Categories: l-TriiodothyronineLorcaserin
go.drugbank.com/drugs/DB04871ApprovedInvestigationalWithdrawnLorcaserin (previously APD-356), a highly selective 5HT2C receptor agonist, is used for the treatment of obesity. … This decision was based on the results of a clinical trial assessing the risk of heart-related problems that found that patients treated with lorcaserin may have a higher risk of cancer.
Perhexiline
go.drugbank.com/drugs/DB01074ApprovedPerhexiline is a coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.
Tepotinib
go.drugbank.com/drugs/DB15133ApprovedInvestigationalIn February 2022, tepotinib was approved for use in Europe.[L42200] … [A228058] MET is a desirable target in the treatment of certain solid tumors as it appears to play a critical role, both directly and indirectly, in the growth and proliferation of tumors in which it is
Pentetreotide
go.drugbank.com/drugs/DB12602ApprovedWithdrawnPentetreotide has been used in trials studying the diagnosis of Cushing's syndrome.
Mixtures: OCTREOSCAN FOR INJECTIONCategories: Compounds used in a research, industrial, or household settingInterferon alfa-2b
go.drugbank.com/drugs/DB00105ApprovedInvestigationalIt is used extensively as an antiviral or antineoplastic agent. … Interferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23.
Mixtures: Rebetron Solution (albumin (human) Free) (18 Miu Multi-dose Pen / 200mg Capsules), Intron ASynonyms: Intron A, Intron A (Interferon α2b)Fenproporex
go.drugbank.com/drugs/DB01550ApprovedIllicitWithdrawnFenproporex is an orally active stimulant drug, which was developed in the 1960s. It is used as an appetite suppressant and a treatment for obesity. … effects are less notorious than with some other agents such as diethylpropion and mazindol. [7] In the United States fenproporex was never approved by the FDA for clinical use due to a lack of efficacy
Products: IFA-DIETY A. P.Midazolam
go.drugbank.com/drugs/DB00683ApprovedIllicitInvestigational[A257153] Midazolam is considered a schedule IV drug in the United States due to the low potential for abuse and low risk of dependence.[L5074] … [L45098] In late 2018, the intramuscular preparation was approved by the FDA for the treatment of status epilepticus in adults.
Products: N/a, DORMICUM ROCHE AMPOULE 5MG/ML